Cargando…

Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration

PURPOSE: Transplantation of human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells offers the potential for benefit in macular degeneration. Previous trials have reported improved visual acuity (VA), but lacked detailed analysis of retinal structure and function in the treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehat, Manjit S., Sundaram, Venki, Ripamonti, Caterina, Robson, Anthony G., Smith, Alexander J., Borooah, Shyamanga, Robinson, Martha, Rosenthal, Adam N., Innes, William, Weleber, Richard G., Lee, Richard W.J., Crossland, Michael, Rubin, Gary S., Dhillon, Baljean, Steel, David H.W., Anglade, Eddy, Lanza, Robert P., Ali, Robin R., Michaelides, Michel, Bainbridge, James W.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195794/
https://www.ncbi.nlm.nih.gov/pubmed/29884405
http://dx.doi.org/10.1016/j.ophtha.2018.04.037
_version_ 1783364458252337152
author Mehat, Manjit S.
Sundaram, Venki
Ripamonti, Caterina
Robson, Anthony G.
Smith, Alexander J.
Borooah, Shyamanga
Robinson, Martha
Rosenthal, Adam N.
Innes, William
Weleber, Richard G.
Lee, Richard W.J.
Crossland, Michael
Rubin, Gary S.
Dhillon, Baljean
Steel, David H.W.
Anglade, Eddy
Lanza, Robert P.
Ali, Robin R.
Michaelides, Michel
Bainbridge, James W.B.
author_facet Mehat, Manjit S.
Sundaram, Venki
Ripamonti, Caterina
Robson, Anthony G.
Smith, Alexander J.
Borooah, Shyamanga
Robinson, Martha
Rosenthal, Adam N.
Innes, William
Weleber, Richard G.
Lee, Richard W.J.
Crossland, Michael
Rubin, Gary S.
Dhillon, Baljean
Steel, David H.W.
Anglade, Eddy
Lanza, Robert P.
Ali, Robin R.
Michaelides, Michel
Bainbridge, James W.B.
author_sort Mehat, Manjit S.
collection PubMed
description PURPOSE: Transplantation of human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells offers the potential for benefit in macular degeneration. Previous trials have reported improved visual acuity (VA), but lacked detailed analysis of retinal structure and function in the treated area. DESIGN: Phase 1/2 open-label dose-escalation trial to evaluate safety and potential efficacy (clinicaltrials.gov identifier, NCT01469832). PARTICIPANTS: Twelve participants with advanced Stargardt disease (STGD1), the most common cause of macular degeneration in children and young adults. METHODS: Subretinal transplantation of up to 200 000 hESC-derived RPE cells with systemic immunosuppressive therapy for 13 weeks. MAIN OUTCOME MEASURES: The primary end points were the safety and tolerability of hESC-derived RPE cell administration. We also investigated evidence of the survival of transplanted cells and measured retinal structure and function using microperimetry and spectral-domain OCT. RESULTS: Focal areas of subretinal hyperpigmentation developed in all participants in a dose-dependent manner in the recipient retina and persisted after withdrawal of systemic immunosuppression. We found no evidence of uncontrolled proliferation or inflammatory responses. Borderline improvements in best-corrected VA in 4 participants either were unsustained or were matched by a similar improvement in the untreated contralateral eye. Microperimetry demonstrated no evidence of benefit at 12 months in the 12 participants. In one instance at the highest dose, localized retinal thinning and reduced sensitivity in the area of hyperpigmentation suggested the potential for harm. Participant-reported quality of life using the 25-item National Eye Institute Visual Function Questionnaire indicated no significant change. CONCLUSIONS: Subretinal hyperpigmentation is consistent with the survival of viable transplanted hESC-derived RPE cells, but may reflect released pigment in their absence. The findings demonstrate the value of detailed analysis of spatial correlation of retinal structure and function in determining with appropriate sensitivity the impact of cell transplantation and suggest that intervention in early stage of disease should be approached with caution. Given the slow rate of progressive degeneration at this advanced stage of disease, any protection against further deterioration may be evident only after a more extended period of observation.
format Online
Article
Text
id pubmed-6195794
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-61957942018-11-01 Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration Mehat, Manjit S. Sundaram, Venki Ripamonti, Caterina Robson, Anthony G. Smith, Alexander J. Borooah, Shyamanga Robinson, Martha Rosenthal, Adam N. Innes, William Weleber, Richard G. Lee, Richard W.J. Crossland, Michael Rubin, Gary S. Dhillon, Baljean Steel, David H.W. Anglade, Eddy Lanza, Robert P. Ali, Robin R. Michaelides, Michel Bainbridge, James W.B. Ophthalmology Article PURPOSE: Transplantation of human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells offers the potential for benefit in macular degeneration. Previous trials have reported improved visual acuity (VA), but lacked detailed analysis of retinal structure and function in the treated area. DESIGN: Phase 1/2 open-label dose-escalation trial to evaluate safety and potential efficacy (clinicaltrials.gov identifier, NCT01469832). PARTICIPANTS: Twelve participants with advanced Stargardt disease (STGD1), the most common cause of macular degeneration in children and young adults. METHODS: Subretinal transplantation of up to 200 000 hESC-derived RPE cells with systemic immunosuppressive therapy for 13 weeks. MAIN OUTCOME MEASURES: The primary end points were the safety and tolerability of hESC-derived RPE cell administration. We also investigated evidence of the survival of transplanted cells and measured retinal structure and function using microperimetry and spectral-domain OCT. RESULTS: Focal areas of subretinal hyperpigmentation developed in all participants in a dose-dependent manner in the recipient retina and persisted after withdrawal of systemic immunosuppression. We found no evidence of uncontrolled proliferation or inflammatory responses. Borderline improvements in best-corrected VA in 4 participants either were unsustained or were matched by a similar improvement in the untreated contralateral eye. Microperimetry demonstrated no evidence of benefit at 12 months in the 12 participants. In one instance at the highest dose, localized retinal thinning and reduced sensitivity in the area of hyperpigmentation suggested the potential for harm. Participant-reported quality of life using the 25-item National Eye Institute Visual Function Questionnaire indicated no significant change. CONCLUSIONS: Subretinal hyperpigmentation is consistent with the survival of viable transplanted hESC-derived RPE cells, but may reflect released pigment in their absence. The findings demonstrate the value of detailed analysis of spatial correlation of retinal structure and function in determining with appropriate sensitivity the impact of cell transplantation and suggest that intervention in early stage of disease should be approached with caution. Given the slow rate of progressive degeneration at this advanced stage of disease, any protection against further deterioration may be evident only after a more extended period of observation. Elsevier 2018-11 /pmc/articles/PMC6195794/ /pubmed/29884405 http://dx.doi.org/10.1016/j.ophtha.2018.04.037 Text en Crown Copyright © Published by the American Academy of Ophthalmology. All rights reserved. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mehat, Manjit S.
Sundaram, Venki
Ripamonti, Caterina
Robson, Anthony G.
Smith, Alexander J.
Borooah, Shyamanga
Robinson, Martha
Rosenthal, Adam N.
Innes, William
Weleber, Richard G.
Lee, Richard W.J.
Crossland, Michael
Rubin, Gary S.
Dhillon, Baljean
Steel, David H.W.
Anglade, Eddy
Lanza, Robert P.
Ali, Robin R.
Michaelides, Michel
Bainbridge, James W.B.
Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration
title Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration
title_full Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration
title_fullStr Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration
title_full_unstemmed Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration
title_short Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration
title_sort transplantation of human embryonic stem cell-derived retinal pigment epithelial cells in macular degeneration
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195794/
https://www.ncbi.nlm.nih.gov/pubmed/29884405
http://dx.doi.org/10.1016/j.ophtha.2018.04.037
work_keys_str_mv AT mehatmanjits transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT sundaramvenki transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT ripamonticaterina transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT robsonanthonyg transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT smithalexanderj transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT borooahshyamanga transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT robinsonmartha transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT rosenthaladamn transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT inneswilliam transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT weleberrichardg transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT leerichardwj transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT crosslandmichael transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT rubingarys transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT dhillonbaljean transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT steeldavidhw transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT angladeeddy transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT lanzarobertp transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT alirobinr transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT michaelidesmichel transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration
AT bainbridgejameswb transplantationofhumanembryonicstemcellderivedretinalpigmentepithelialcellsinmaculardegeneration